Iovance Biotherapeutics Says Cervical Cancer Drug Has 11% Response Rate in Study

Iovance Biotherapeutics (IOVA) said Friday its drug LN-145 achieved an 11% complete response rate in a follow-up study of patients with advanced cervical cancer.

The company noted that the median duration of response (DOR) had yet to be reached in the trial.

“The duration of response of current second line treatments for advanced cervical cancer are in the range of three to five months,” said study investigator Dr. Emese Zsiros. “The observation in the study of LN-145 that median DOR has not yet been reached at a median of 7.4 months following treatment provides evidence that this therapy could provide a clinically meaningful improvement over currently available options.”

In addition, an ongoing study of the treatment lifileucel showed two complete responses and 23 partial responses in patients with advanced melanoma, the company said. The disease control rate was 80%.